-TT

Haiqiong Zheng1,2,3, Houli Zhao1,2,3, Shi Han1,2,3

  • 1Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China.

PubMed
概括

化学抗原受体 (CAR) -T细胞疗法在治疗T细胞恶性瘤方面面临挑战,原因是T细胞相似性,导致诸如兄弟杀戮和无形性等问题. 本综述探讨了改善T细胞癌的CAR-T细胞疗法的当前局限性和策略.